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Introduction 
 
This toxicology laboratory guide has been written for medical, nursing and support 
staff who avail of The HSE Drug Treatment Centre (HSE-NDTC) drug analysis 
service. It provides general information on how to access this service and details the 
range of tests available. 
 
The Drug Analysis Laboratory provides a national drug analysis service to the HSE 
Addiction Services, general practitioners, hospitals (general, psychiatric and 
maternity), juvenile detention centres, voluntary organisations, and the Dublin Drug 
Court Probation Service.  
 
 
I welcome the 7
th
 publication of this user guide and I commend the hard work of the 
laboratory team for its compilation and distribution. 
 
 
 
 
 
Siobhan Stokes 
Principal Biochemist 
HSE-NDTC Laboratory 
July 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © the HSE National Drug Treatment Centre Laboratory 
This document shall not be reproduced except in full without the written approval of the laboratory of 
The HSE National Drug Treatment Centre Laboratory.
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General Information 
 
 
Address:  HSE National Drug Treatment Centre 
 
McCarthy Centre  
 
30-31 Pearse Street  
 
Dublin 2 
 
D02 NY26 
 
 
 
Principal Biochemist: Ms. Siobhan Stokes  
 
 
Opening Hours of Laboratory: Mon – Fri 
 
                                                                         8.45am - 5.00pm 
 
Laboratory Tel. Nos.: 
 
Enquiries:  01-6488645 
 
Principal Biochemist:  01-6488644 
 
Laboratory e-mail:     lab@dtcb.ie 
 
 
 
Website:     www.addictionireland.ie
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Samples for Drug Analysis 
 
Many different types of biological samples can be tested for drugs including urine, blood, oral fluid and hair. 
Here at the NDTC we screen urine and Oral Fluid for drugs of abuse. 
 
Table 1: Drug detection times in biological matrices 
 
 
 
 
 
 
Urine 
Urine is the most commonly used specimen due to its ease of collection and long window of detection 
(drugs can be detected for a number of days, and in some cases, weeks, after last use). It is the universally 
preferred sample to screen for the presence or absence of drugs. However, urine is unsuitable for 
determining drug levels due to the many factors which influence the composition and concentration of 
urine.  
 
Blood 
The only blood testing done in the NDTC is therapeutic monitoring of blood methadone levels. (see page 7 
for further information). 
 
Oral fluid (Saliva) 
Oral fluid collection may be time consuming and the volume of oral fluid is small. Drug levels in oral fluid are low 
compared to levels found in urine and in addition levels of drugs and their metabolites have a shorter 
window of detection in comparison to urine. However collection of oral fluid can be supervised without any 
invasion of privacy. 
  
Hair 
Hair can demonstrate a historical record of drug use, however the NDTC do not provide this service.  
 
 
 
Consent 
 
The HSE NDTC Drug Analysis Laboratory does not take responsibility for obtaining “consent to test” for 
samples received for drug testing. 
Consent should be obtained by the doctor or organisation requesting the test, prior to sending samples to 
the laboratory. If the client is under 18 years old, consent should be obtained from a parent or guardian. 
 
 
 
 
 
 
 
 
 
 
Sample type Detection time range Drug use detected 
Oral fluid 0-48 hours Acute, under the influence 
Blood 0-48 hours Acute, under the influence 
Urine Days - weeks Recent 
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Packaging and Transport 
 
Samples should be packaged according to United Nations (UN) regulations. Under these regulations 
samples are divided into two groups: 
1)  Diagnostic: a specimen collected for the purpose of diagnosis. 
2) Infectious: a specimen containing a viable microorganism that is known, or reasonably believed, to 
cause disease. 
 
UN approved packaging consists of a triple packaging system: 
• Primary receptacle – the urine bottle. This must be leak-proof, sealed securely, clearly labeled 
and wrapped in enough absorbent material to absorb all fluid in case of breakage. 
• Secondary receptacle - used to enclose the primary receptacle. This must be durable and leak-
proof. Several primary receptacles may be placed in one secondary receptacle. Sufficient additional 
absorbent material must be used to cushion multiple primary receptacles. 
• Outer packaging – the secondary receptacle is placed in an outer package which protects it and 
the contents from outside influences such as physical damage and / or water while in transit. 
 
Supply 
UN3373 approved packaging is available commercially from third parties (please contact the laboratory 
directly if you require further information). 
 
NOTE: It is the responsibility of the sender   to   ensure   the   correct   designation,   packaging, labeling 
and documentation of all specimens. 
 
Sample Collection 
 
The procedure for sample collection is detailed in Table 2 below (Standard precautions and procedures 
should be followed when sampling). 
 
Table 2: Sample collection  
Sample Type Collection Details 
Urine  Use clean plastic container without preservative. Preferably 70 ml 
yellow lidded Sarstedt urine pots. 
 20 - 30mls where possible. 
 Where collection bottle with temperature strip is used temperature of 
urine should be between 34-39
0
C when freshly voided. 
 Sample should be stored in a cool, dry dark place (preferably 
refrigerated) pending dispatch to the laboratory 
 Sample should be dispatched  to Laboratory as soon as possible 
Oral Fluid  Use Quantisal collection device (no other collection device will be 
accepted) 
 Observe donor 10-15mins without food or drink prior to collection. 
 Supervise collection (approx. 5 mins). 
Blood (Serum Methadone only)  Serum Red Cap Tube  with 10 mls where possible 
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Sample Label Information 
 
The following information is mandatory and must be included on the sample container; 
 
1. Patients full name 
2. Date of Birth 
3. Name or assigned code of clinic or hospital 
4. Date of sample collection 
 
Request forms are not necessary: any extra testing can be requested by writing the test required on the 
sample label. 
 
In addition the following information may be required on some samples 
1. Name of Doctor 
2. DAIS Code 
 
 
Note: failure to include the correct information prevents the processing of a sample. 
 
 
Non-Compliant Samples 
 
Non-compliant samples are samples which do not demonstrate the mandatory information required to 
identify a particular sample, i.e. full name, date of birth, sample date and location from which the sample 
was sent.  
 
Samples missing any of the aforementioned data cannot be analysed. The laboratory will make every effort 
to obtain the correct sample identification in order to proceed with analysis. 
 
Leaking samples are non-compliant samples. Leaking samples will not be analysed and the sample will 
be disposed of immediately. 
 
Notification of non-compliances will be sent to the sender by means of a comment on report or a non-
compliance form, detailing the nature of the non-compliance.  
 
 
 
Request Forms 
 
Request forms are available on the HSE NDTC web site (www.addictionireland.ie), however forms are 
NOT required for routine screening. Additional tests can be requested by writing the test code on sample 
bottle. See table of test abbreviations in Additional Non –Routine Testing Table 4. 
Request forms for blood methadone testing are also available on the website and should accompany all 
blood methadone requests  
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Range of Testing 
 
Testing is divided into several categories including: 
 Testing for adulteration  
 Routine urine screening 
 Additional non-routine urine screening  
 Confirmatory analysis  
 Oral fluid screening  
 Serum Methadone levels.  
See details in the Table 3 below. (See page 5) 
 
Testing for adulterants   
Adulteration testing refers to tests carried out to determine whether a sample is genuine or if it has been 
tampered with. Methods of urine adulteration include dilution with, addition of, or substitution by, a drug-
free substance or solution.  
 
Dilution is the most common method of adulteration used by drug users to evade detection of misuse. 
Creatinine levels in urine can indicate the extent of this dilution, therefore all samples received for analysis 
are tested for Creatinine.  
 
 ‘Normal’ urine should have a Creatinine level in the range 80-200mg/dL.  
 
 ‘Dilute’ urine is indicated by a Creatinine level of less than 20mg/dL. 
         
 ‘Abnormal’ urine is indicated by a Creatinine level of <2mg/dL.  
 No test results will be reported on samples deemed to be ‘abnormal’. 
 
Abnormal pH readings will indicate tampering of a sample by the addition of or substitution by, another 
substance or liquid. 
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 Table 3: Range of Testing 
 
Please Note: Turnaround time is measured from time of receipt of sample at the laboratory 
Abbreviations: 
6-AM: 6-acetylmorphine, primary metabolite of heroin;  EtG – Ethyl Glucuronide (Alcohol biomarker) 
EDDP:  2-ethylidine-1,5-dimethyl-3,3-diphenylpyrrolidine; primary metabolite of methadone 
LC-MS: Liquid Chromatography Mass Spectrometry; IA:  Immunoassay; Screen: Screening Test 
 
1. Moeller et al Urine Drug Screening: Practical Guidelines for Clinician Mayo Clin Proc Jan 2008 83(1):66-76 
2. Cedia Package Insert 
3. Objective testing-Urine and other drug tests. Hadland and Levy Child Adolesc Psychiatr Clin N Am 2016 25(3) 549- 
565 
4. Robert Kronstrand Journal of Analytical Toxicology, Vol. 32, October 2008 
 
 
 
Sample 
type 
Test Type Method Test Window of 
Detection 
Normal 
Turnaround 
Times 
Included in 
Scope of 
Accreditation 
Urine Routine 
Screen 
IA Opiate Class 2-4 days
1
 24-48 hours Yes 
6-AM 24 hours
2 
 
Yes 
Benzodiazepine 
Class 
3-30 days
1
 Yes 
EDDP Unknown Yes 
Cannabis class 1-30 days
1
 Yes 
Cocaine 2-4 days
1
 Yes 
Amphetamine Class 1-2 days
1
 Yes 
Enzymatic Alcohol 7-12 hours
1
 Yes 
Chemical Creatinine n/a Yes 
Non-
Routine 
Enzymatic Pregnancy n/a No 
Chemical pH n/a Yes 
Glucose n/a No 
IA EtG – Alcohol marker Up to 48 
hours
3 
Yes 
Buprenorphine 4-24 hours
4
  Yes 
Confirm LC-MS 
 
Opiate Identification  5-10 days 
 
No 
Zopiclone  No 
‘Headshop’ products 
(psychoactive 
substances) 
Bathsalts only 
 No 
THC-COOH 
(Cannabis 
metabolite) 
 No 
LC-MS Benzodiazepine 
identification 
 No 
Oral Fluid Screen IA Opiate Class 1-36 hours
3
 5-10 days Yes 
6-AM unknown Yes 
Benzodiazepine 
Class 
unknown Yes 
Methadone unknown Yes 
Cannabis class Up to 24 
hours
3
 
Yes 
Cocaine 1-36 hours
3
 Yes 
Amphetamine  1-48 hours
3
 Yes 
Blood Screen IA Methadone levels n/a  No 
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4 
Routine Screening Analysis 
 
The majority of drug testing performed by the laboratory falls into this category. Routine screening is 
carried out by immunoassay, enzyme assay or chemical assay. These are rapid methods used for 
screening drugs of misuse. Tests included in the routine screen are detailed in table 3 above. 
 
Immunoassay is a qualitative method which indicates only the presence or absence of a drug/drug class 
in a sample. 
 
Each test by immunoassay has a defined cut-off level, above which the test is deemed positive indicating 
that the presence of a drug/drug class was detected above the cut-off level.  
If a test result falls below the cut-off level, the result is deemed negative indicating that the drug/drug class 
was not detected above the cut-off.  
Cut-off levels are detailed on every test report. 
 
With the exception of alcohol, the current format used does not give any information about the level or 
concentration of the drug present. 
 
It should be noted that all analytical results are subject to Uncertainty of Measurement (UoM), *see 
section on Uncertainty of Measurement (page 11). The performance of qualitative test results around the 
cut-off concentration is routinely monitored by the use of quality controls which are run with every batch of 
samples. Clinical consideration and judgment should be applied to all immunoassay test results. 
Confirmatory analysis may be requested for a positive drug screening result if required. (See page 8) 
 
 
 
Additional non routine testing 
 
Additional tests not routinely performed on samples include 6-Acetylmorphine (6-AM) the primary 
metabolite of Heroin, Zopiclone, Buprenorphine, ‘Headshop’ drug analysis (New Psychoactive substances, 
see Appendix 4), pregnancy testing, pH, glucose and Ethyl Glucuronide (EtG). 
These tests are carried out on request only.  These requests can be made by writing the test abbreviation 
on the sample bottle/label.  
 
Table 4 Test abbreviations for additional tests 
 
Drug Abbreviation 
Heroin Metabolite 6-AM 
Ethyl Glucuronide EtG 
Suboxone/Buprenorphine Bupn 
Zopiclone/Zimmovane ZOP 
Opiate ID OPIA ID 
Tramadol Tram 
Pregnancy hcG 
Headshop Hshop 
Full Screen FS 
Oxycodone Oxy 
 
 
The full range of analyses available is indicated in Table 3 (page 5). 
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 ‘True and ‘False’ Positives 
 
Care should be taken when interpreting immunoassay screening results, as some over the counter drugs 
will give ‘true’ positive results. An example of this is Solpadeine®   which will give a positive opiate result 
because it contains codeine, which is also classified as an opiate type drug.  
Some drugs and medications can also produce ‘ false’ positive results when tested using 
immunoassay, due to cross reactivity and further confirmatory analysis may be necessary. This cross 
reactivity occurs most commonly with opiate and amphetamine drug classes.  
A study carried out in our laboratory showed that for the CEDIA® Amphetamine/Ecstasy assay, cross 
reaction was occurring with other compounds particularly new psychoactive substances such as 
cathinones (‘Headshop’ Drugs/Bath Salts/Legal Highs).  If you have any queries about an amphetamine 
positive result please contact the laboratory. Confirmatory analysis can be carried out on request. 
Benzodiazepines,   cannabis,   cocaine   and   EDDP immunoassay tests are relatively specific and 
rarely produce false positive results.  See Appendix 1 for table of cross-reactivity for urine kits.  
Because of cross-reactivity, screening results by immunoassay alone are not legally defensible and further 
confirmation of the test result is required depending on the purpose of the testing.  
 
 
Therapeutic drug monitoring of Methadone 
 
Therapeutic drug monitoring of methadone is performed to identify rapid Methadone metabolisers and can 
help with titrating Methadone dosages, provided other factors are considered when interpreting the 
result, e.g. sex, weight, time of dose, time of sampling etc. ( It is always important to treat the patient, not 
the level). 
 
Blood samples should only be submitted for serum Methadone level testing if the following criteria have 
been adhered to: 
 
CRITERIA 
 
•   A minimum of 3 days supervised Methadone consumption prior to the day of blood collection. 
•   The time of dosing on each day should be the same +/- 30 minutes. 
•   The blood sample must be taken immediately before the next dose on day 4. 
•   The time must be the same as the previous 3 days +/- 30 minutes. 
•   Samples must be collected into a serum tube. 
•   The sample must be accompanied by a request form/ letter which includes time of dose on previous 
day, time of dose on day of sampling and time of blood collection. 
 
Failure to adhere to these guidelines will result in unreliable data and defeat the purpose of carrying out 
the procedure. 
 
Therapeutic levels of Methadone: 
‘With chronic administration of 100-200 mg daily oral doses to tolerant subjects, the plasma concentration 
peaked at 4 hours, with an average value of 0.83ug/ml (range, 0.57 -1.06) and declined to 0.46mg/L 
(range, 0.28-0.79) 24 hours after last dose (average plasma half life of 25 hours).’  
‘It has been estimated that trough plasma methadone levels should be at least 0.05 - 0.10 mg/L to prevent 
withdrawal systems in narcotic maintenance patients (i.e. 50-100ng/ml)’. 
[Baselt 2004, Disposition of Toxic Drugs and Chemicals in man, 6
th
 edition, p. 642 – 643] 
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Confirmatory Analysis 
 
Confirmatory analysis is carried out using liquid chromatography mass spectrometry (LC-MS).  
See Table 3 (page 5) and Appendices 2, 3 and 4 for further details. 
 
 
 
 
Oral Fluid testing 
 
Oral Fluid tests include Opiates, Benzodiazepines, Methadone, Amphetamine, Cocaine, Cannabis and 6-
Acetylmorphine (the primary metabolite of heroin). The methods are accredited for using the Quantisal
®
 
collection devices and no other collection device will be accepted (product code QS-0025) available from 
Alere Toxicology PLC (Concateno) 0044-1235861483. 
 
Depending on the drug used, dosage and route of administration, a drug may be detected in oral fluid in 
less than one hour after use and remain detectable up to 48 hours after last use. 
Substances such as food, beverages, over-the-counter medication, and mouthwash can affect the oral 
fluid drug test results. For this reason, before collection of saliva or oral fluid, the collector should observe 
the donor for a 10-15 min period in which the donor should not smoke, consume food or drink. 
The full range of analyses available is indicated in Table 3 (page 5). 
 
 
Subcontracted testing 
 
When a request is received from a customer for a test which is not performed, the laboratory may as a 
service to the customer, subcontract the testing, if required. In this instance, the laboratory will endeavour 
to subcontract the testing request to a competent external laboratory which complies with ISO 17025 or 
equivalent. The Laboratory does not subcontract tests within the scope of its accreditation. 
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Chain of Custody 
 
In order for test results to be defensible in a court of law or professional hearing, chain of 
custody procedures must be followed.   
 
Chain of custody involves fully documenting who donated, collected and handled the sample thereafter. 
The HSE NDTC laboratory can provide information on chain of custody collection kits and sampling 
procedures. All positive immunoassay screening test results must be confirmed by a second analysis 
using a confirmatory analytical method.  
 
For further information, please contact Laboratory Customer Services. 
 
 
 
Storage and Retention of Samples 
 
Samples should be sent to the laboratory at the earliest opportunity. If there is any delay, it is 
recommended that samples are stored in a refrigerator at 4ºC, or if refrigeration is not available, in a cool 
dark place. Post analysis, the laboratory will retain samples for 14 days in refrigerated conditions, after 
which they will be disposed of safely. Should further testing be required outside of this period (e.g. for 
Zopiclone analysis) samples will be stored in refrigerated conditions until testing is complete. 
        
Unless otherwise agreed, all Chain of Custody samples will be frozen and retained for 12 months and 
all Probation samples will be frozen and retained for 12 months post analysis. 
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Reporting of Results 
 
The front page of each report details the customer name and address, date on which each report is 
generated and scope of INAB accreditation (for accredited tests only). 
 
Each patient is identified by name, date of birth, clinic code and chart number.  
 
Each sample is identified by a unique barcode and sample date.    
   
If a drug/drug class is detected in a sample, the result will appear as a "+" (positive), indicating the 
presence of the drug.  
 
When no drug/drug class has been detected, it will be reported as a "-" (negative), indicating that the 
drug/drug class has not been detected above the cut-off level or concentration.  
 
A blank space indicates that no test was carried out. Screening results will be available within 24-48 
hours of receipt of samples in the laboratory. Confirmatory testing usually takes longer to perform due 
to the complexity of the methodology. 
 
Mode of reporting 
The method of report transmission used must be agreed in advance with Laboratory Customer Services. 
Routine modes of reporting available are post or electronically (LER, DAIS).  
 
Post: 
Reports sent by post will be dispatched as soon as possible after completion of analysis. 
 
Fax: 
The laboratory no longer faxes reports as per HSE policy. 
 
 
Electronic Reporting 
 
Drugs Aids Information System (DAIS): HSE Addiction Service defined user’s access laboratory results via 
DAIS. This is completed once the laboratory authorises the samples. 
 
Laboratory Electronic Reporting (LER): The LER is a web-based system developed for NDTC customers 
which allows authorised users to access results electronically. Sample results are available in the system 
as soon as the analysis is complete.  
 
Verbal reporting:  
Verbal reporting can only be accommodated in the case of an emergency.
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Measurement Uncertainty 
 
When interpreting laboratory reports, consideration should always be given to the Measurement 
Uncertainty (MU) associated with the test result, because no measurement is absolutely exact.  
When a quantity is measured, the outcome depends on the measuring system, e.g. test procedure, 
environmental conditions, volumetric effects, reference values, sampling matrix, operator etc. Therefore all 
measurements are subject to uncertainty and this should be taken into account in the interpretation of 
laboratory results. This can have a bearing on immunoassay test results which are close to their cut-off 
point and therefore within the range of measurement uncertainty for the test cut-off.  
Clinical consideration and judgment should be applied to any immunoassay test result. Repeat testing or 
confirmatory analysis may be requested if required. The tests reported are qualitative with the exception of 
Alcohol which is quantitative. 
 
Measurement Uncertainty 
 
The figures for each test are given in brackets  
URINE TESTS  
OPIATE (+/-19.5%)
a
, 6-AMOR (+/-21.6%)
a
, BENZ (+/-13.5%)
a
, EDDP (+/-12.2%)
a
, CANN (+/- 20.0%)
b
, AMPH (+/-
16.6%)
a
, COCA (+/-9.2%)
a
, ALCO (+/-12.4%)
a
, ETG (+/-17.6%)
a
, BUP (+/-27.6%)
a
, pH (+/- 6.5%)
a 
a = based on all 2017 QC data    b= based on 6 months 2018 QC data 
ORAL FLUID TESTS 
OPIATE (+/-14.9%)
c
, 6-AMOR (+/-27.9%)
c
, BENZ (+/-28.3%)
c
, CANN (+/-39.4%)
c
, AMPH (+/-7.2%)
c
, COCA (+/-25.1 
%)
c
, METH (+/-34.0%)
c 
c = based on 2018 validation data 
 
Quality Control and Quality Assurance 
 
To ensure the highest confidence in test results, the laboratory adheres to strict quality control (QC) and 
quality assurance (QA) standards. (Approx. 3% of all samples run are quality controls).  
 
In order to assess performance, the laboratory is involved in five external Quality Assurance schemes:  
 LGC – Drugs of abuse in urine, Ethanol in urine and Drugs in Oral Fluid 
 Irish External Quality Assessment Scheme (IEQAS) – Drugs of abuse in urine. 
 Arvecon – Ethylglucuronide in urine 
 
          
Viewing of quality control data, proficiency testing data, and testing procedures will be accommodated on 
request by arrangement with the laboratory. 
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10 
Accreditation 
 
Accreditation is the third party confirmation of an organisation’s competence and integrity to perform 
testing services. Accreditation is objective proof that an organisation has the competence to comply with 
best practice. It is the internationally recognised system that is used to develop and sustain high standards 
of performance. It is often a prerequisite for eligibility to tender for international projects. Accreditation is 
provided by the national accreditation body for each Member State and in Ireland this is the Irish National 
Accreditation Board (INAB). 
 
The HSE National Drug Treatment Centre Laboratory is accredited by the Irish National Accreditation 
Board (INAB) to undertake testing as detailed in the Schedule bearing the Registration number 169T which 
is available at: 
 
http://www.inab.ie/Directory-of-Accredited-Bodies/Laboratory-Accreditation/Testing/HSE-National-Drug-
Treatment-Centre.html 
 
See also Table 3. (Page 5) 
 
Testing in the scope of accreditation is carried out in conformity with ISO/IEC 17025:2005 2nd Edition 
´General requirements for the competence of testing and calibration laboratories’.  
 
ISO 17025 is the standard used by testing and calibration laboratories globally. The laboratory is assessed 
annually for compliance with International standard ISO 17025 by a team of Irish and international 
external auditors. This includes assessment of the organisations quality management system and the 
technical competence of the laboratory to perform the tests applicable to its scope of accreditation. 
 
 
 
Membership and Representation 
 
To ensure best practice and to keep up to date with the latest developments and trends in drug misuse, 
laboratory staff have professional membership and attend meeting of various international societies, 
these include:- 
ACBI – Association of Clinical Biochemists of Ireland 
TIAFT - The International Association Forensic Toxicologists 
UKIAFT - UK and Ireland Association of Forensic Toxicologist 
 
The laboratory is also represented at the Early Warning and Emerging Trends (EWET) committee of the 
National Advisory Committee on Drugs (NACD)
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Appendix 1 
Urine Immunoassay Cross Reactivity Tables 
(Ref: Thermofisher Scientific CEDIA Drugs of abuse documentation) 
 
CEDIA
®
 Amphetamine/Ecstasy Assay (cut – off 1000ng/mL)* Drugs producing positive results 
Amphetamine 
Methamphetamine 
 
N-Methylbenzodioxazolylbutanamine 
(MBDB)  
3,4-Methylenedioxyamphetamine (MDA)  
 
3,4-Methylenedioxyethylamphetamine 
(MDEA)  
3,4-Methylenedioxymethamphetamine 
(MDMA) 
 
 
CEDIA
®
  Opiate Class  (cut-off conc.300 ng/ml) Drugs producing positive results 
6-Monoacetylmorphine  
Diacetylmorphine  
Hydrocodone  
Hydromorphone  
Morphine  
 
Morphine Sulfate  
Nalorphine HCl  
Naloxone 
Naltrexone HCl  
Oxycodone  
Oxymorphone  
Pholcodine  
Thebaine 
 
CEDIA
®
  Benzodiazepine Class (cut-off conc. 300ng/ml) Drugs producing positive results 
Alprazolam 
Bromazepam 
Chlordiazepoxide 
Citalopram 
Clobazam 
Clonazepam 
Delorazepam 
Demoxepam 
 
Diazepam 
Estazolam 
Flunitrazepam 
Flurazepam 
Halazepam 
Lormetazepam 
Medazepam 
Midazolam 
 
Nimetazepam 
Nitrazepam 
Nordiazepam 
Oxazepam 
Prazepam 
Temazepam 
Tetrazepam 
Triazolam 
 
 
 
CEDIA
®
  6-Acetylmorphine (10 ng/ml) Drugs producing positive results 
6-Acetylmorphine  
 
 
CEDIA
®
  Cannabis  (cut-off conc.50 ng/ml) Drugs producing positive results 
11-Nor- -9-THC-COOH  
11-Nor  8-THC-COOH  
 9-THC (Dronabinol)  
 11-Hydroxy-- 9-THC  
1- -9-THC-Glucuronide  
8-OH- -9-THC  
 
8β,11-di-OH- -9-THC  
Cannabinol 
 
 
 
CEDIA
®
  Cocaine (cut-off conc. 300 ng/ml) Drugs producing positive results 
Benzoylecgonine  
Cocaethylene 
 
Cocaine 
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DRI
®
 Ethyl Alcohol (mg/dL) Drugs producing positive results 
Ethanol 
 
CEDIA
®
  EDDP (cut-off conc. 100ng/mL) Drugs producing positive results 
2-Ethylidin-1,5-dimethyl-3,3-diphenylpyrrolidin (EDDP)  
 
 
Immunanlysis
®
 Buprenorphine (cut-off conc. 5ng/mL) Drugs producing positive results 
Norbuprenorphine 
 
 
DRI
®
 Ethyglucuronide (cut-off conc. 500ng/mL) Drugs producing positive results 
Ethyglucuronide  
 
NB. The above lists are not exhaustive – Please contact the laboratory if confirmation of a positive result is required 
 
We have found that CEDIA® Amphetamine/Ecstasy assay may cross-react with other compounds particularly  
new psychoactive substances (‘Headshop’ Drugs/Bath Salts/Legal Highs). If you have any queries about  
an amphetamine positive result please contact the laboratory. Confirmatory analysis can be carried out on request. 
 
Oral Fluid Immunoassay Cross Reactivity 
 
We have limited information on cross-reactivity for Oral Fluid tests. Triazolam (Halcion) causes  
false positive results for 6-Acetylmorphine (6-AM) oral fluid test in patients who are prescribed this drug. 
Patients on Halcion are therefore unsuitable for oral fluid testing. Urine testing should be used for these 
patients. 
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Appendix 2 
Benzodiazepine Identifications 
 
The routine immunoassay screening method for benzodiazepines is unable to distinguish between 
metabolites, therefore urinary benzodiazepine identifications are carried out where required using a more 
complex technique called LC/MS which can specifically target and unambiguously identify the drug or 
metabolite present.  
 
Benzodiazepines can be short-acting or long acting and depending on the drug taken. They can persist for 
an extended time in the urine of habitual users even after all use has ceased. A further complication is that 
the metabolic pathways of benzodiazepines can often result in common metabolites (the most significant 
being Oxazepam) and this means that in many cases it may not be possible to determine the parent drug. 
Therefore it can be difficult to unambiguously identify which parent drug(s) was originally consumed. 
 
See Table 5 below.  
Many factors such as how much fluid has been consumed prior to giving the sample, the time since the 
drug was taken, the physical condition and metabolism of the patient etc. may influence the dilution of a 
urine sample and therefore the drug level present. Therefore drug levels in urine may be subject to large 
fluctuations. If urine is dilute, drug levels will be lowered. Consequently urinary levels of benzodiazepines 
are not performed in the NDTC Laboratory 
 
Table 5 Benzodiazepines and their metabolites 
 
 
 
Parent Drug Target Drug/Metabolite(s) Tested 
Alprazolam hydroxyalprazolam, Alprazolam 
Bromazepam Bromazepam 
Chlordiazepoxide Chlordiazepoxide, Nordiazepam, Oxazepam, 
demoxepam 
Clobazam Clobazam 
Clonazepam Clonazepam, 7-aminoclonazepam 
Diazepam  Diazepam,Nordiazepam,Oxazepam,Temazepam 
Estazolam Estazolam 
Flunitrazepam Flunitrazepam, 7-Aminoflunitrazepam 
Flurazepam 2-Hydroxyethylflurazepam 
Lorazepam Lorazepam  
Midazolam Midazolam 
Nitrazepam Nitrazepam 
Oxazepam Oxazepam 
Prazepam Oxazepam 
Temazepam Temazepam, Oxazepam 
Triazolam Triazolam, a-hydroxytriazolam 
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Appendix 3 
Opiate Identifications 
 
The routine screen by immunoassay will be positive when certain opiates are present in the urine sample at 
a concentration above the cut-off concentration of 300ng/ml 
 Heroin, Morphine, Codeine and Dihydrocodeine will cause a positive result in the screening assay 
when present at levels above the cut-off.  
 Naloxone (present in Suboxone) can also cause an opiate positive on the routine screen at very high 
levels.  Not all patients on Suboxone will have opiate positive urines, it usually occurs in patients that 
are on high levels of Suboxone 
 Oxycodone has also been known to cause a positive at extremely high levels, at therapeutic levels it 
should not cause a positive. 
 Tramadol does NOT cause a positive on the routine screen 
If the routine test is opiate positive and further analysis is requested in order to determine the source of the 
opiate positive, a 6-AM screening test can be performed on the sample. As 6-AM is a unique metabolite of 
Heroin it is only present in urine after recent ingestion of Heroin, a positive 6-AM result indicates that Heroin 
has been taken in the past 10 to 24 hours. A 6-AM negative result may indicate either that the ingestion of 
heroin is not recent or that the individual has not taken Heroin and that the sample is opiate positive due to a 
non heroin opiate.  An opiate positive, 6 -AM negative test can be subjected to further testing by LC/MS in 
order to determine what opiate has been taken. 
Metabolism of Opiates 
Because of the similar metabolic pathways of some opiates it can be difficult to distinguish between the use 
of Heroin, Morphine or Codeine, or the use of a combination of more than one of these because both 
Morphine and Codeine may be present after Heroin use, Morphine use or after Codeine use.  If more 
Codeine than Morphine is present in a sample it would indicate that Codeine has been ingested.  If more or 
similar levels of morphine and codeine are present in a sample it is not possible to definitively determine 
which drug was taken. 
Drug Taken Metabolites/Drugs found 
Heroin 6-AM and Morphine, Codeine (as impurity) 
Codeine Codeine and Morphine 
Dihydrocodeine Dihydrocodeine 
Morphine Morphine 
Oxycodone Oxycodone and Oxymorphone 
Naloxone Naloxone 
 
If Tramadol or Oxycodone analysis is requested this must be specifically requested as Opiate ID for 
Tramadol or Oxycodone.  
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Appendix 4 
New Psychoactive substances (NPS) 
The terms ‘Legal highs’, ‘Head Shop products’ or  ‘New Psychoactive Substances’ refer to a new drugs with 
stimulant or psychoactive effects which had not been encountered as drugs of abuse or recreational drugs 
until recent years. Initially these were sold as ‘legal’ highs in so-called ‘Head Shops’ in Ireland and via the 
internet.  Various legislative changes led to these being controlled drugs and the so called ‘Head Shops’ 
were closed down.  Unfortunately the controls put in place have not eliminated the use of these substances 
and they are still in use in the illicit drug market. 
The Laboratory of the HSE-NDTC is currently testing in the order of 500 samples annually for New 
Psychoactive Substances (on request only). The profile of drugs detected over the years has changed over 
time and the panel of drugs screened is updated periodically to include more recent variants in the 
compounds tested and as reference standards become available. 
The parent drug is looked for in these analyses, as little is known about the metabolism of these drugs and in 
general, drug standards of the metabolites are not yet commercially available. There may be metabolites of 
these compounds that are present in higher concentrations than the parent in the urine and present for a 
longer time than the metabolite.    It is not known how long any of these compounds are present in the urine. 
The laboratory does not test for the synthetic Cannabinoids (Spice compounds) it only tests for the powders 
or “bath salts”.  A negative result for the ‘Headshop ‘test does not mean that an individual has not taken a so 
called ‘Headshop’ drug, it just means that they have not taken one of the compounds tested for in our assay. 
For the latest information on these products and the legislation relating to them, refer to www.drugs.ie and 
the Irish Legislation website http://www.irishstatutebook.ie 
For the latest information on NPS in Europe see the EMCDDA annual report and other publications on the 
EMCDDA website http://www.emcdda.europa.eu/ 
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